Navigating the Invisible: How Cell Therapy Manufacturers Are Overcoming Particulate Inspection Challenges

In the rapidly evolving landscape of regenerative medicine and cell-based therapies, the manufacturing process is fraught with technical hurdles that differentiate it from traditional small-molecule pharmaceuticals. Among the most pressing of these challenges is the detection and control of particulate matter. Because cell-containing products are inherently opaque and often stored in specialized freezing bags, standard visual inspection protocols—designed for clear, aqueous solutions—are frequently inadequate.

As the industry matures, manufacturers are increasingly turning to creative process engineering and surrogate testing to satisfy regulatory expectations. According to Diana Colleluori, PhD, a principal chemistry, manufacturing, and controls (CMC) consultant at Biologics Consulting, the lack of explicit regulatory guidance on particulates in these novel products has forced the industry to adopt a proactive, data-driven methodology to ensure patient safety.

The Core Challenge: Why Cell Therapies Defy Conventional Inspection

Traditional injectable drugs undergo rigorous visual inspection under standardized lighting to ensure they are free of foreign matter. However, cell therapies, such as CAR-T cell products or stem cell-derived treatments, present a unique set of variables.

The Problem of Opacity

"Processing and testing cell-containing products already has inherent challenges because they cannot be terminally sterilized," explains Colleluori. "It is also significantly harder to make a visual assessment to meet regulatory requirements because they already contain cells, and the final product is usually packaged in a cell-freezing bag."

Because the product itself is a suspension of biological material, the density and turbidity of the fluid mask the presence of foreign particulates. Furthermore, the storage containers—typically ethylene-vinyl acetate (EVA) or similar polymers—are often semi-opaque or textured, further complicating manual or automated visual inspections.

Sources of Contamination

Colleluori notes that approximately 90% of identified particulates in these processes are plastic fragments. These typically migrate into the product during contact with single-use systems (SUS)—the tubing, bags, and connectors that dominate modern bioprocessing facilities. Additional particulates can be introduced during manual handling or product manipulation. Minimizing these contact points is a primary goal for quality-by-design (QbD) teams, yet it remains impossible to eliminate them entirely.

Chronology of Regulatory Evolution

The regulatory framework for cell therapies has been playing "catch-up" with the rapid clinical adoption of these products. Historically, the pharmaceutical industry relied on USP for sub-visible particles and USP / for visible particles. These standards were built on the assumption of clear, stable liquids.

1. The Era of Conventional Small Molecules: For decades, regulators demanded 100% inspection for visible particulates. The standards were black and white: if it’s visible, it’s a failure.
2. The Rise of Biologics: As monoclonal antibodies entered the market, the industry had to grapple with protein aggregation. Inspection became more nuanced, but the products remained mostly clear.
3. The Advent of Advanced Therapy Medicinal Products (ATMPs): In the last decade, cell-based products exploded into the clinic. Regulators found that existing guidance did not account for the biological "noise" of cells.
4. The Current Pivot: Manufacturers are now moving away from "attempted inspection" of the final product and toward "process validation" to prove that the manufacturing environment is sufficiently clean.

Supporting Data and Methodological Innovations

To bridge the gap between current limitations and regulatory mandates, companies are employing a "surrogate testing" strategy. This approach allows for a rigorous assessment of the manufacturing process without relying on the impossible task of inspecting the final, opaque product.

The Surrogate Buffer Method

Colleluori describes a common practice among her clients: running the full manufacturing process using only the formulation buffer, excluding the cells.

"By running the process with the formulation buffer, you create a clear solution that is not contained in a standard freezing bag," she explains. "This allows the manufacturer to assess particulates in a clear environment, which can then be extrapolated to the process running with cells. By testing visible and sub-visible particles in those samples, you can prove your product contact materials are expected to meet the limits for your cell-containing products."

Quality Control (QC) Protocols

While the surrogate method validates the process, QC teams must still test the final product. These tests are adapted from established pharmacopeial standards but are applied with a contextual understanding of the administration method:

• USP and : Used for the visual inspection of injections. While the cells make the product look "dirty," experts look for distinct foreign matter that differs from the cellular suspension.
• USP : Used for sub-visible particles. Because cell therapies are often administered as suspensions, the thresholds for sub-visible particles must be adjusted to ensure that the counts are not simply identifying the therapeutic cells themselves.

Official Responses and Regulatory Expectations

Regulatory bodies, including the FDA and EMA, have increasingly signaled that they expect a risk-based approach. If a manufacturer cannot perform a 100% visual inspection, they must provide a robust scientific justification for why their process controls are sufficient to mitigate risk.

The Role of Administration Routes

The stringency of the regulatory requirement is heavily dependent on how the patient receives the therapy. Colleluori emphasizes that context is everything:

"If you are doing an intramuscular injection, the regulatory scrutiny is likely less rigorous than for an intrathecal injection. The latter involves the delivery of the product directly into the spinal canal or brain, which carries significantly higher risks regarding particulate-induced inflammation or blockage."

As a result, manufacturers of intrathecal or intravenous products must employ more advanced testing technologies, such as light obscuration or flow imaging microscopy, to characterize the particle profile of their therapeutic batches.

Implications for the Industry

The current approach to particulate control has profound implications for the cost and speed of bringing cell therapies to market.

Process Standardization

The reliance on single-use equipment means that vendors of bags, tubing, and filters are under increased pressure to provide "clean" components. Manufacturers are increasingly auditing their suppliers for particulate shedding data. The burden of proof is shifting from the final inspection of the vial to the qualification of the entire supply chain.

The "Cost of Quality"

Implementing surrogate testing and advanced QC protocols adds significant time and expense to the CMC development phase. However, as Colleluori points out, this is a necessary investment. "The industry is moving toward a model where you build quality into the process. You cannot inspect quality into a cell therapy at the end of the line."

Future Trends: Automation and AI

Looking forward, the industry is eyeing machine learning and computer vision to solve the opacity problem. Advanced imaging algorithms are being developed to differentiate between cellular aggregates and foreign plastic particulates in real-time. By training AI models on thousands of images of "clean" versus "contaminated" suspensions, manufacturers may one day be able to perform automated, non-destructive inspections of opaque cell products.

Conclusion: A Paradigm Shift in Quality Assurance

The challenge of particulate matter in cell therapy is a perfect microcosm of the broader challenges facing regenerative medicine. We are attempting to use the manufacturing standards of the 20th century to govern the biological complexities of the 21st.

Diana Colleluori’s work highlights that while the lack of explicit guidance is a hurdle, it is not a dead end. By moving toward surrogate testing, rigorously qualifying contact materials, and tailoring inspection levels to the route of administration, the industry is establishing a new standard of "Process-Oriented Quality."

As regulatory agencies continue to provide more clarity on ATMPs, manufacturers who have already invested in these rigorous, risk-based frameworks will be best positioned to scale their therapies and, ultimately, ensure that life-saving treatments reach patients without the risk of preventable complications. The "invisible" nature of these particles is no longer a valid excuse for poor control; instead, it has become a catalyst for a higher, more sophisticated level of biopharmaceutical manufacturing excellence.